滴通鼻炎水喷雾剂治疗变应性鼻炎的临床研究

目的 评价滴通鼻炎水喷雾剂治疗变应性鼻炎(鼻鼽)的临床疗效和安全性.方法采用随机、盲法、安慰剂平行对照、多中心临床研究,88例变应性鼻炎患者分为试验组66例、对照组22例,分别使用滴通鼻炎水喷雾剂和安慰剂,外用喷鼻,每次2揿(0.13 mL/揿),4次/d,疗程14 d.用变应性鼻炎临床疗效、鼻塞缓解时间、鼻塞缓解维持...     

氮卓斯汀鼻喷雾剂联合氯雷他定治疗过敏性鼻炎的效果分析

目的探讨氮卓斯汀鼻喷雾剂联合氯雷他定治疗过敏性鼻炎的临床效果。方法 80例过敏性鼻炎患者,随机分为试验组和对照组,各40例。对照组患者给予氮卓斯汀鼻喷雾剂联合孟鲁司特钠治疗,试验组给予氮卓斯汀鼻喷雾剂联合氯雷他定治疗。比较两组患者临床疗效以及症状缓解时间。结果试验组总有效率为95.0%高于对照组的80.0%,差异有统计学意义(P<0.05)。试验组鼻塞缓解时间(3.3±1.2)d、鼻痒缓解时间(4.2±1.1)d、流鼻涕缓解时间(8.2±1.1)d均低于对照组的(3.9±1.4)、(5.1±1.2)、(9.1±1.3)d,差异有统计学意义(P<0.05)。结论对过敏性鼻炎患者采用氮卓斯汀鼻喷雾剂联合氯雷他定治疗,其临床效果显著,能明显缩短患者临床症状缓解时间,具有较大临床推广价值。     

辛夷鼻炎丸治疗急、慢性鼻炎及变应性鼻炎多中心随机对照试验

目的通过临床试验客观评价其临床疗效及安全性,进一步考察辛夷鼻炎丸对急慢性鼻炎及变应性鼻炎的疗效,申报国家中药保护品种。方法将452例临床确诊的急慢性鼻炎及变应性鼻炎患者按单纯随机方法分为两组(试验组304例和对照组138例)。急性鼻炎:试验组,口服辛夷鼻炎丸一次3g,3次/d,共5d;对照组,口服芎菊上清丸一次6g,2次/d,共5d;慢性鼻炎及变应性鼻炎:试验组,口服辛夷鼻炎丸一次3g,3次/d,共28d;对照组,开水冲服通窍鼻炎颗粒,一次2g,3次/d,共28d,比较两组疗效并观察药物不良反应。结果急性鼻炎、慢性鼻炎、变应性鼻炎总有效率,试验组分别为98.31%、98.40%、93.44%,对照组分别为98.31%、97.96%、90.00%,说明两组药物治疗慢性鼻炎总疗效相似,未发现明显不良反应及毒副作用。结论辛夷鼻炎丸治疗急性鼻炎(外感风热证)、慢性鼻炎及变应性鼻炎是安全和有效的。     

中西医结合治疗以鼻塞为主症的常年性变应性鼻炎疗效观察

目的观察加味补中益气汤结合丙酸倍氯米松喷雾剂治疗以鼻塞为主症的常年性变应性鼻炎临床疗效。方法将82例患者随机分为2组,治疗组45例采用加味补中益气汤口服结合丙酸倍氯米松喷雾剂喷鼻治疗,对照组37例采用丙酸倍氯米松喷雾剂喷鼻治疗。观察患者治疗前后症状、体征变化。结果治疗组显效率为75.56%高于对照组的54.05%,治疗组总有效率为95.56%高于对照组为83.78%,差异均有显著性意义（P〈0.05）。治疗后2组鼻塞、鼻腔体征积分均有显著改善（P〈0.01）,治疗组优于对照组,差异有统计学意义（P〈0.05）。结论加味补中益气汤结合丙酸倍氯米松喷雾剂治疗常年性变应性鼻炎以鼻塞为主症者疗效确切。     

曲安奈德鼻喷雾剂治疗过敏性鼻炎的临床研究

目的评价曲安奈德鼻喷雾剂治疗过敏性鼻炎的临床疗效及安全性,方法以丙酸倍氯米松鼻喷雾剂(商品名伯克纳)为对照药,采用开放性、随机对照、多中心临床试验的方法治疗过敏性鼻炎160例.剂量用法曲安奈德鼻喷雾剂,鼻腔喷入,每次每鼻孔2揿,每日1次,每揿55μg;丙酸倍氯米松鼻喷雾剂,鼻腔喷入,每次每鼻孔2揿,每日2次,每揿50μg.疗程均为2周.结果曲安奈德鼻喷雾剂与丙酸倍氯米松鼻喷雾剂临床疗效评价例数分别为100例和60例,两药临床有效率分别为8 8%和90%,药物不良反应发生率分别为13%和10%.以上结果经统计学处理均无显著差异(P＞0.05).结论曲安奈德鼻喷雾剂治疗过敏性鼻炎安全有效.     

鼻渊通窍颗粒联合糠酸莫米松鼻喷雾剂治疗儿童过敏性鼻炎的临床研究

目的探讨鼻渊通窍颗粒联合糠酸莫米松鼻喷雾剂治疗儿童过敏性鼻炎的临床疗效。方法选取2017年8月—2018年10月在广东省妇幼保健院就诊的110例过敏性鼻炎患儿作为研究对象,按照随机数字表法将全部患者分为对照组和治疗组,每组各55例。对照组睡前鼻吸入糠酸莫米松鼻喷雾剂,2揿/鼻孔,1次/d。治疗组在对照组治疗的基础上温水口服鼻渊通窍颗粒,15 g/次,3次/d。两组患者均连续治疗8周。观察两组的临床疗效,比较两组的临床症状体征、血清因子指标。结果治疗后,对照组和治疗组的总有效率分别为78.18%、92.73%,两组比较差异具有统计学意义(P0.05)。治疗后,两组的喷嚏、鼻塞、流涕、鼻痒、体征评分均明显降低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗后,治疗组的喷嚏、鼻塞、流涕、鼻痒、体征评分均低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组的嗜酸粒细胞阳离子蛋白(ECP)、免疫球蛋白E(IgE)、血清细胞间黏附分子-1(ICAM-1)水平均显著降低,同组治疗前后差异具有统计学意义(P0.05);且治疗后,治疗组的ECP、IgE、ICAM-1水平均低于对照组,两组比较差异具有统计学意义(P0.05)。结论鼻渊通窍颗粒联合糠酸莫米松鼻喷雾剂治疗儿童过敏性鼻炎具有较好的临床疗效,可改善临床症状体征,降低ECP、IgE、ICAM-1水平,具有一定的临床推广应用价值。     

糠酸莫米松鼻喷雾剂联合通窍鼻炎片治疗变应性鼻炎的疗效观察

目的探究糠酸莫米松鼻喷雾剂联合通窍鼻炎片治疗变应性鼻炎的临床疗效。方法选取2013年7月—2014年1月常州市第三人民医院门诊收治的变应性鼻炎患者160例,将患者随机分为试验组(100例)和对照组(60例)。对照组采用糠酸莫米松鼻喷雾剂治疗,试验组采用糠酸莫米松鼻喷雾剂联合通窍鼻炎片治疗。比较两组患者治疗后的疗效和不良反应发生率。结果试验组总有效率(88.0%)高于对照组(80.0%),差异有统计学意义(P<0.05)。对照组有3例患者出现不良反应,其中鼻腔干燥感2例,声嘶1例;观察组有5例患者出现不良反应,其中鼻腔干燥感1例、鼻黏膜出血1例、关节疼痛与腹痛1例、睡眠障碍1例和皮疹1例,上述不良反应症状均较轻,未予处理均逐渐自行消失。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论糠酸莫米松鼻喷雾剂联合通窍鼻炎片治疗变应性鼻炎的效果显著,不良反应小。     

鼻内镜手术后使用布地奈德鼻喷雾剂治疗慢性鼻-鼻窦炎伴变应性鼻炎的临床观察

目的:探讨鼻内镜手术后使用布地奈德鼻喷雾剂治疗慢性鼻-鼻窦炎伴变应性鼻炎的临床疗效及安全性。方法:将120例慢性鼻-鼻窦炎伴变应性鼻炎患者按随机数字表法分为对照组和试验组,各60例。两组患者均行鼻内镜手术。对照组患者术毕1周后给予生理盐水灌洗鼻腔;试验组患者术毕1周后给予布地奈德鼻喷雾剂喷鼻,早晚各1次。两组患者疗程均为3个月。比较两组患者治疗前后变应性鼻炎相关症状评分及临床疗效,利用光镜和电镜对鼻腔黏膜的超微结构进行观察,并统计不良反应发生情况。结果:治疗前,两组患者变应性鼻炎症状评分比较,差异无统计学意义(P>0.05);治疗后,两组患者变应性鼻炎症状评分显著降低,且试验组显著低于对照组,差异均有统计学意义(P<0.05)。试验组患者临床总有效率为94.83%,明显高于对照组的50.00%,差异有统计学意义(P<0.05)。两组患者治疗后鼻腔黏膜病理性腺体增生及黏膜水肿均明显改善,差异有统计学意义(P<0.05),但组间比较,差异无统计学意义(P>0.05)。试验组患者鼻腔黏膜修复时间(3个月)显著短于对照组(6个月),差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:鼻内镜手术后使用布地奈德鼻喷雾剂治疗慢性鼻-鼻窦炎伴变应性鼻炎疗效显著,能明显改善患者变应性鼻炎相关症状,修复鼻腔黏膜的超微结构,且安全性较好。     

辛芩颗粒治疗小儿鼻炎150例

目的　观察口服辛芩颗粒治疗小儿急、慢性 ,过敏性鼻炎的临床疗效及毒副作用。方法　治疗组 15 0例选用辛芩颗粒 ,按每岁每次口服 1克 ,每日 4次 ;对照组 15 0例中 5 0例每次用扑尔敏按 0 35mg·kg口服 ,每日 4次 ,两组连续用药 7～ 10d。结果　治疗组总有效率为 96 7% ,无明显不良反应 ;对照组总有效率为 76 7%。两组总有效率有显著差异性 (P <0 0 0 5 )。结论　辛芩颗粒能改善小儿伤风鼻塞 (急性鼻炎 )、鼻窒 (慢性鼻炎 )、鼻鼽 (过敏性鼻炎 )的临床症状     

孟鲁司特钠咀嚼片联合糠酸莫米松鼻喷雾剂治疗儿童过敏性鼻炎的临床研究

目的探讨孟鲁司特钠咀嚼片联合糠酸莫米松鼻喷雾剂治疗儿童过敏性鼻炎的临床疗效。方法选择2013年10月—2014年5月在重庆市中医院就诊的过敏性鼻炎患儿96例,随机分为对照组和治疗组,每组48例。对照组患儿使用糠酸莫米松鼻喷雾剂,每侧鼻孔100μg/次,1次/d。治疗组患儿在对照组的治疗基础上口服孟鲁斯特钠咀嚼片,5 mg/次,1次/d。两组患儿均连续治疗14 d。观察两组的临床疗效,比较两组患者鼻炎总体症状、流涕、鼻痒、喷嚏、鼻塞等评分的变化,同时检测两组白细胞介素10(IL-10)、干扰素γ(IFN-γ)、IL-4、Ig E的变化。结果治疗后,对照组和治疗组的总有效率分别为87.5%、100.0%,两组总有效率比较差异有统计学意义(P0.05)。治疗7、14 d两组患儿喷嚏、流涕、鼻塞、鼻痒评分、症状总评分均较治疗前显著降低,同组治疗前后差异有统计学意义(P0.05);且治疗组的改善程度优于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组患儿的IL-4、Ig E显著降低,IL-10、IFN-γ水平均有明显升高,同组治疗前后差异有统计学意义(P0.05);但治疗组这些检测因子的改善程度优于对照组,两组比较差异有统计学意义(P0.05)。结论孟鲁司特钠咀嚼片联合糠酸莫米松鼻喷雾剂治疗儿童过敏性鼻炎具有较好的临床疗效,可有效降低症状评分,调节鼻炎相关因子水平,值得临床推广应用。     

糠酸莫米松鼻喷雾剂联合孟鲁斯特钠咀嚼片治疗儿童中重度过敏性鼻炎的疗效及安全性

目的 研究糠酸莫米松鼻喷雾剂联合孟鲁斯特钠咀嚼片治疗儿童中重度过敏性鼻炎的疗效及安全性.方法 研究对象选自2011年9月至2012年3月在同济医学院附属同济医院门诊就诊的6～12岁中重度过敏性鼻炎患儿.将患儿按就诊时间的先后顺序用随机数字法分为2组:联合用药组和单独用药组.联合用药组采用糠酸莫米松鼻喷雾剂100 μg/d联合孟鲁斯特钠咀嚼片5 mg/d,单独用药组单用糠酸莫米松鼻喷雾剂100 μg/d治疗,疗程均为2周.治疗第7、14天采用0～10 cm视觉模拟量表进行过敏性鼻炎总体症状和喷嚏、流涕、鼻痒、鼻塞症状评分,记录不良反应.结果 共入选患儿252例.联合用药组127例,男54例,女73例,平均年龄(8.1±2.6)岁;单独用药组125例,男58例,女67例,平均年龄(8.7±3.0)岁.2组患儿性别、年龄分布、病程、鼻炎总体症状及单个症状评分比较差异均无统计学意义(均P>0.05).联合用药组有2例患儿因用药后出现关节疼痛、腹痛和睡眠障碍而退出研究.与治疗前相比,治疗第7、14天鼻炎总体症状评分联合用药组分别下降(4.7±1.9)和(5.5±2.2)分[(2.6±1.7)、(1.8±1.7)分比(7.3±1.3)分],单独用药组下降(3.9±2.2)和4.9±1.7分[(3.2±2.0)、(2.3±2.1)分比(7.2±1.5)分],差异均有统计学意义(均P<0.05),联合用药组改善程度优于单独用药组(P<0.05).单项症状评分中,治疗第7、14天联合用药组对流涕和鼻塞症状的疗效均优于单独用药组(均P<0.05).联合用药组有5例发生不良反应(3.9%),其中与糠酸莫米松鼻喷雾剂相关的不良反应为鼻出血(2例)和鼻腔干燥(1例),与孟鲁斯特钠咀嚼片相关的不良反应为关节疼痛、腹痛(1例)和睡眠障碍(1例);单独用药组有4例发生不良反应(3.2%),鼻腔干燥和鼻出血各2例.2组间不良反应发生率差异无统计学意义(P>0.05).2组患儿不良反应均较轻微,停药后很快自行缓解.2组均无严重不良反应发生.结论 糠酸莫米松鼻喷雾剂联合孟鲁斯特钠咀嚼片治疗儿童中重度过敏性鼻炎疗效优于单用糠酸莫米松鼻喷雾剂,且安全性良好.     

氮斯汀喷鼻剂治疗常年性变应性鼻炎随机双盲试验

目的 :探讨氮斯汀喷鼻剂治疗常年性变应性鼻炎的疗效及安全性。方法 :38例中、重度常年性变应性鼻炎病人行随机、双盲、对照研究。分氮斯汀组 19例 ,给予氮斯汀液体喷鼻剂喷鼻 ,每日 2次 ,每次每侧鼻孔 1揿 (每揿 140 μg氮斯汀 ) ,治疗 4wk。左卡巴斯汀组 19例 ,用左卡巴斯汀喷鼻剂喷鼻 ,每日 2次 ,每次 2揿 ,作为对照。治疗 2wk末及 4wk末时 ,根据主观评分及客观检查结果 ,综合评定疗效。结果 :氮斯汀喷鼻剂组总有效率为 95 % ,左卡巴斯汀喷鼻剂组为 84 % (P >0 .0 5 )。 2组治疗前后喷嚏、流涕、鼻痒、鼻塞及眼部症状积分下降分别为 1.4± 0 .8和 1.3± 1.0 ,1.0±0 .7和 0 .8± 0 .9,1.3± 0 .6和 1.4± 0 .7,0 .7± 0 .7和 0 .7± 0 .8,0 .8± 0 .8和 0 .5± 0 .7(均P >0 .0 5 ) ,未发生严重的不良反应。结论 :氮斯汀喷鼻剂与左卡巴斯汀喷鼻剂在治疗常年性变应性鼻炎时具相似的疗效和安全性     

Efficacy and safety of intranasally applied dimetindene maleate solution. Multicenter study in children under 14 years suffering from seasonal allergic rhinitis

The aim of this study was to investigate the efficacy and tolerability of intranasally applied dimetindene (CAS 3614-69-5) 0.1% spray in children suffering from seasonal allergic rhinitis. A total of 100 children under 14 years with acute seasonal allergic rhinitis participated in this randomised, single-blind, reference-controlled, multi-center, parallel group study with two treatment groups. The study took place between 2nd April and 16th September 1996 during the pollen season. Patients were examined at enrollment (day 1), day 8 and day 15. Patients kept diary throughout the 2-week treatment phase. Patients were randomised to receive either dimetindene 0.1% (Fenistil Nasal Spray) or a levocabastine (CAS 79516-68-0) 0.05% solution as reference medication. Both medications were supplied in similar outer packages. A single-blind approach was chosen, because the reference medication levocabastine requires two spray puffs per nostril as a single dose, whereas for dimetindene maleate solution a single spray puff per nostril is sufficient. Dimetindene 0.1% was applied with 1 spray puff (= 0.14 mg dimetindene) in each nostril and levocabastine with 2 spray puff (= 0.10 mg levocabastine) in each nostril every day in the morning before leaving the house and in the evening before going to bed. Additional administration of the spray was allowed up to 4 times a day if needed. Efficacy was assessed as change in severity of characteristic symptoms associated with pollen rhinitis: nasal rhinorrhea, nasal itching, nasal sneezing and nasal congestion. In addition, changes in ocular symptoms, lacrimation, ocular itching and red eyes, global physician's assessment of efficacy at the end of treatment were assessed. The primary criterion change of total nasal symptom severity score between day 1 and day 3 resulted in a statistically equivalent and therapeutically relevant symptom reduction for the two treatments. All secondary criteria showed a similar reduction in symptoms, thus underlining the consistency of the findings. Both nasal sprays were well tolerated. It is concluded from these results that dimetindene 0.1% nasal spray solution is a safe and efficient treatment option for children under 14 years suffering from seasonal allergic rhinitis.     

曲安奈德喷雾剂对变应性鼻炎的作用

目的研究曲安奈德鼻腔局部给药对实验性变应性鼻炎动物模型的治疗作用及对组胺致大鼠鼻气道阻力增加的缓解作用。方法以实验性变应性鼻炎模型豚鼠和组胺致鼻气道阻力增加模型大鼠为试验对象 ,以豚鼠鼻腔分泌物量、喷嚏次数、搔鼻次数、鼻组织学及大鼠鼻气道阻力为指标 ,全面考察曲安奈德喷雾剂对变应性鼻炎的作用。结果曲安奈德鼻喷雾剂 (5 0、10 0、2 0 0 μg·kg-1,对卵蛋白致敏实验性变态反应性鼻炎豚鼠模型的各种变应性鼻炎的症状和体症均有明显改善作用 ;与模型对照组比较 ,各给药组动物鼻腔分泌物量、喷嚏次数、抓鼻次数明显减少 ,并可对抗组胺所致大鼠鼻气道阻力的增加。结论曲安奈德鼻喷雾剂鼻腔局部给药对实验性变应性鼻炎有显著改善作用     

敏停喷鼻剂对TDI致豚鼠过敏性鼻炎模型的影响

目的研究敏停喷鼻剂对豚鼠过敏性鼻炎模型的影响。方法用TDI致豚鼠过敏性鼻炎造模型，观察敏停喷鼻剂对过敏性鼻炎模型的鼻部过敏症状以及鼻黏膜病理组织形态学的影响。结果敏停喷鼻剂能明显减轻豚鼠过敏性鼻炎模型鼻部过敏症状以及鼻黏膜上皮炎细胞的浸润。结论敏停喷鼻剂对过敏性鼻炎可能具有较好的疗效。     

A comparison of the efficacy and tolerance of an aqueous beclomethasone dipropionate nasal spray with the conventional pressurized spray

Summary

Forty-two subjects took part in a double-blind, double-dummy, parallel group study to compare the efficacy and tolerance of a nasal spray containing an aqueous suspension of beclomethasone dipropionate with the conventional pressurized spray in controlling the symptoms of seasonal rhinitis. Each patient received 100 μg beclomethasone dipropionate into each nostril twice daily for 14 days. Evaluation of daily symptom scores, and the physician's and subjects’ assessment of treatment, demonstrated that both sprays were equally effective in alleviating symptoms and with a similar low incidence of side-effects. The aqueous spray may be considered an effective alternative treatment in the management of seasonal rhinitis.     

盐酸氮卓斯汀喷鼻剂与辅舒良在治疗变应性鼻炎中的疗效分析

目的比较盐酸氮卓斯汀喷鼻剂同辅舒良在治疗常年性变应性鼻炎中的疗效。方法在确诊为常年性变应性鼻炎的231例患者,随机分成两组,其中123例患者对其用盐酸氮卓斯汀喷鼻剂进行治疗,另外108例用辅舒良(丙酸氟替卡松鼻喷剂)进行治疗,对比两组的疗效。结果盐酸氮卓斯汀组与辅舒良组治疗效果相当,但盐酸氮卓斯汀起效时间更快。从不良反应看,盐酸氮卓斯汀有个别患者诉有一过性轻微口苦;辅舒良组有10例出现鼻黏膜干燥,有3例出现鼻出血。盐酸氮卓斯汀不良反应更少。结论当常年性变应性鼻炎需要快速、安全和高效减轻症状时盐酸氮卓斯汀喷鼻剂是重要的选择之一。     

Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis

OBJECTIVE: The objective of the study was to evaluate the effectiveness of azelastine (Astelin) nasal spray, a topical second-generation antihistamine, in the treatment of symptoms of seasonal allergic rhinitis, seasonal allergic rhinitis with nonallergic triggers (mixed rhinitis), and nonallergic vasomotor rhinitis. RESEARCH DESIGN AND METHODS: A total of 2343 primary care physicians, allergists, ENT specialists, and other health professionals participated in this 2-week, open-label evaluation of azelastine nasal spray. Data were collected through a physician questionnaire that included patient demographics, rhinitis diagnosis, medication history, and inclusion/exclusion criteria; and two patient questionnaires that included symptom history, response to previous rhinitis medications, symptom control, and level of satisfaction with azelastine nasal spray. A completed physician questionnaire and two completed patient questionnaires were required for each patient to be included in the analysis. Patients who qualified for enrollment were given open-label azelastine nasal spray and instructed to administer 2 sprays per nostril twice daily for 2 weeks. RESULTS: A total of 1225 health professionals enrolled 7864 patients into the study. Completed physician and patient questionnaires were returned by 1081 health professionals and 5073 patients, 4364 of whom used azelastine nasal spray as their only rhinitis medication during the 2-week study period. The patients were predominantly caucasian (82.6%) and female (61.1%), with a mean age of 50 years. The majority had a diagnosis of mixed rhinitis (51.5%), followed by seasonal allergic rhinitis (32.3%), and nonallergic (vasomotor) rhinitis (16.2%). After 2 weeks of treatment, the percentage of patients reporting some control or complete control of individual symptoms ranged from 78% for postnasal drip in patients with nonallergic vasomotor rhinitis to 90% for sneezing in patients with seasonal allergic rhinitis. More than 85% of patients who reported difficulty sleeping or impairment of daytime activities due to rhinitis symptoms had improvement in these parameters. Azelastine nasal spray was well tolerated, the discontinuation rate due to adverse events was 2.3%. CONCLUSIONS: Azelastine nasal spray was reported to control all rhinitis symptoms, including nasal congestion, regardless of rhinitis diagnosis during the 2-week study period. Patients with seasonal allergic rhinitis and patients with seasonal allergic rhinitis plus nonallergic triggers were identified as patient types most likely to respond to azelastine nasal spray.     

布地奈德鼻喷雾剂和地氯雷他定片联合治疗过敏性鼻炎

目的探讨布地奈德喷雾剂和地氯雷他定片联合应用治疗过敏性鼻炎的疗效。方法 150例确诊为过敏性鼻炎的患者分为3组,分别给予布地奈德鼻喷雾剂和地氯雷他定片(联合组)50例,布地奈德喷雾剂(单药A组)50例,地氯雷他定片(单药B组),观察2周,并对治疗前后的症状和体征记分比较。结果联合组的近期疗效总有效率达96%,单药A组为75%,单药B组为68%,联合组效果明显优于单药A组和单药B组,无明显的不良反应。结论布地奈德鼻喷雾剂和地氯雷他定片联合治疗过敏性鼻炎安全有效。